Safety
ADVERSE EVENT
In total, 109 participants received elamipretide and 109 received placebo. AEs during the treatment period were reported by a higher percentage of elamipretide-treated participants (98.2% [n = 107/109]) than placebo-treated participants (76.1% [n = 83/109]) (Adverse Events for Participants in the Elamipretide and Placebo Groups